コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 dually decreased, while HS showed only minor decease.
2 or tropical cassava during sharp temperature decease.
3 splant and terminated when all patients were deceased.
4 am veterans who were alive in the 1980s were deceased.
5 observed SCr in a cohort of living (79) and deceased (67) donor allograft recipients followed up ove
7 er factors impacting allograft survival from deceased AA kidney donors, APOL1 renal-risk variants wer
8 brain tissues of alcohol-dependent rats and deceased alcoholics, primarily in frontal and striatal a
10 at compassionate and respectful care for the deceased and family, listening for and addressing family
11 he impact of the quality of the care for the deceased and for the family, (5) the content and manner
12 s to determine the effect of HLA matching on deceased and LD renal allograft outcomes in pediatric re
13 magnify and modify extant ethical issues in deceased and living donation related to privacy, confide
14 al, 0.32 to 1.01) ml/min per 1.73 m(2) among deceased and living donor kidney transplant recipients,
15 n addressing a diversity of issues including deceased and living organ donation, improving allograft
16 ucted, using variations of the search terms "deceased" and "controls" to identify relevant peer-revie
19 been explored that regulate the clearance of deceased cardiomyocytes by using the classic and reparat
23 ing child is older and less prominent if the deceased child was either disabled or an infant, suggest
25 trated in postmortem ocular investigation of deceased children using immunohistochemical staining for
26 iew highlights the breadth of research using deceased controls and indicates their appropriateness in
30 sought on study design, rationale for using deceased controls, application of theoretical principles
33 l and ethical issues pertaining to pediatric deceased donation and developed recommendations for poli
34 s the routine provision of opportunities for deceased donation by pediatric patients and conveys an i
40 tion Society convened a meeting on pediatric deceased donation of organs in Geneva, Switzerland, on M
41 s with voluntary, unpaid programs; associate deceased donation with being poor and marginal in societ
46 modeling showed divided-dose-rATG (P=0.019), deceased donor (P=0.003), serious infection (P=0.0.018),
47 waiting list or received a transplant from a deceased donor (waiting-list-or-transplant control group
49 d, in which ALA was administered both to the deceased donor and to the recipients; and (iii) recipien
50 rfusion biopsy associate with outcomes after deceased donor but not living donor renal transplants, t
52 gan Sharing database (2002-2011) queried for deceased donor first LT for primary biliary cirrhosis, p
53 ed the outcomes of 5,230 recipients of first deceased donor grafts transplanted during the period of
54 or even in need of, a kidney transplant, and deceased donor initiated chains in which chains are star
55 Replacement of pancreatic beta-cells through deceased donor islet transplantation is a proven therapy
58 y Allocation System (KAS), a major change to deceased donor kidney allocation, was implemented in Dec
59 erstanding of factors that lead to increased deceased donor kidney discard can allow for targeted int
65 ted with the observed SCr in both living and deceased donor kidney recipients, correlation was strong
66 observed SCr was significantly greater among deceased donor kidney recipients, suggesting poorer func
67 zation, graft loss was substantially higher (deceased donor kidney transplant [DDKT] without delayed
68 gan Sharing data from 2003 to 2012 for adult deceased donor kidney transplant candidates was analyzed
70 cells were measured by flow cytometry in 76 deceased donor kidney transplant recipients (DGF, n = 18
71 F and graft loss in pediatric and adolescent deceased donor kidney transplant recipients aged 21 year
72 an adult female patient who presented for a deceased donor kidney transplant with incidental finding
74 ealthier recipients and increasing access to deceased donor kidney transplantation (DDKT) for highly
75 nephropathy or ADPKD) than by lower rates of deceased donor kidney transplantation after waitlisting
77 within 3 years of transplantation in 19 450 deceased donor kidney transplantation recipients with Me
82 for Organ Sharing data, we identified first deceased donor kidney transplants between October 1, 198
84 a retrospective cohort analysis of pairs of deceased donor kidney transplants where 1 kidney was all
85 ers, Shiraz undertakes the largest number of deceased donor kidney transplants, most liver transplant
87 tes who declined IRDs later received non-IRD deceased donor kidney transplants; the median KDPI of th
91 om 2003 to 2013, we identified recipients of deceased donor kidneys from the same donor in such a way
92 K Transplant Registry data were collected on deceased donor kidneys implanted between November 1, 201
93 , 66.3% of living donor kidneys and 50.7% of deceased donor kidneys received an optimal histology sco
96 iopsy findings at the time of procurement of deceased donor kidneys remain the most common reason cit
97 of histologic classification, outcomes with deceased donor kidneys were inferior to outcomes with li
101 r each involved party, the prioritization of deceased donor kidneys, the allocation of chain ending k
107 nd Thymoglobulin appear equally effective in deceased donor KTRs maintained on tacrolimus/mycophenola
109 nd recipient characteristics associated with deceased donor liver organ offers for children who died
110 etherlands, DCDs were responsible for 30% of deceased donor liver transplant activity in 2015; Austri
111 ective review of 1300 patients who underwent deceased donor liver transplantation was performed.
115 d of patients aged >/=18 years who underwent deceased donor LT between January 1, 2003, and December
117 edures that included acceptance criteria for deceased donor organ pancreata and critical raw material
122 mentation, including the allocation of fewer deceased donor pediatric kidneys to children and stagnat
126 0.04) more likely to experience MDR, as were deceased donor recipients (adjusted hazard ratio [aHR],
129 of this study was to compare the outcomes of deceased donor renal allografts preserved with these flu
131 theater that impact significantly on CIT in deceased donor renal transplantation, some of which are
135 o a 10-year-old child using a decellularized deceased donor trachea repopulated with the recipient's
136 nsplantation should be promoted by expanding deceased donor transplant programs and use of inexpensiv
137 morbidity score of 5 or greater, receiving a deceased donor transplant reduced the mortality risk by
140 s a single-center retrospective study of all deceased donor transplants from 2004 to 2010 (n=359).
141 he expected survival benefits of living over deceased donor transplants were not present in membranop
142 aft survival was compared between living and deceased donor transplants within each glomerulonephriti
144 and implementing the logistical workflow for deceased donor uterus procurement in a deceased multiorg
146 and our own initial experience, in which the deceased donor uterus was procured post cross-clamp and
147 tions regarding the most advantageous use of deceased donor versus living donor transplantation for p
149 en during late adolescence, and differential deceased donor waiting times based on pediatric priority
152 largest recovery of 11 organs from a single deceased donor with the transplantation of face, bilater
153 lls compared with high-fidelity simulations (deceased donor) (Nontechnical Skills video score: 95% CI
155 s older than 65 years were transplanted with deceased donor, the mortality risk was reduced by 55% (h
156 rs for post-kidney transplantation SSIs were deceased donor, thin ureters at kidney transplantation,
163 hether a patient will receive an offer for a deceased-donor kidney at Kidney Donor Profile Index thre
167 le-center, observational study involving 319 deceased-donor kidney transplant recipients, we assessed
168 associated with worse allograft survival in deceased-donor kidney transplantation (DDKT) from AA don
170 transplants is limited to a small number of deceased-donor kidney transplants from HIV-positive to H
174 d cohort analysis, obtaining data from every deceased-donor kidney-alone transplant procedure perform
176 ero' biopsies for 371 consecutive, solitary, deceased-donor kidneys transplanted at our center betwee
180 ed associations between injury biomarkers in deceased-donor urine and the following outcomes: donor A
181 patients (panel reactive antibody > 80%), a deceased-donor-first strategy was advantageous, but for
182 ew listings (IRR, 1.02; P = 0.003), 100 more deceased donors (IRR, 1.23; P < 0.001), 100 more new dia
184 ir application to the conduct of research on deceased donors and donor organs within the United State
185 atty acid binding protein (L-FABP) from 1304 deceased donors at organ procurement, among whom 112 (9%
189 ective as using high-fidelity anatomies from deceased donors for promoting teamwork skills in this le
192 rative data can be used to identify possible deceased donors in the US and could be a data source for
193 act that kidney transplantation from elderly deceased donors is associated with reduced graft and pat
195 ated chains in which chains are started with deceased donors rather than altruistic living donors.
196 ation of organs from HIV-positive living and deceased donors to HIV-positive individuals with end-sta
200 e than that of transplants from well-matched deceased donors with 0 to 1 HLA mismatch (log rank, P =
201 nsplantation, graft survival of kidneys from deceased donors with 0 to 1 HLA mismatches compares favo
202 The outcomes of recipients of organs from deceased donors with ITP recorded in the UK Transplant R
204 00 kidneys (>17% of the total recovered from deceased donors) were discarded in 2013, despite evidenc
205 1 genotype differed from the genotype of the deceased donors, allowing us to differentiate liver- fro
211 donation percentage (percentage of possible deceased-donors who become actual donors; range: 20.0-57
212 ly higher density in live versus prematurely deceased females indicating a potentially mutualistic as
214 April 30, 2017, ocular tissue samples from 4 deceased fetuses with a diagnosis of CZS from the Nation
218 Donors in the older group were mostly women deceased from stroke, and only 3 patients had experience
219 sequenced from lung samples originating from deceased giant pandas all possessed the substitutions V2
222 andomized, open-label, monocenter trial, 160 deceased heart-beating donors were allowed to perform 23
223 val 0.39 - 0.72), effects that translated to deceased hospital length of stay [median hospital length
224 e interval [95% CI], 0.11-0.65) and standard deceased (HR, 0.52; 95% CI, 0.29-0.94) donor kidney tran
225 METHODS AND Small bowel was obtained from deceased humans, cows, and sheep supported with a contin
226 ta, we assessed patients with ovarian cancer deceased in 2000 to 2012 with at least 13 months of cont
227 8 to 395 months), 22 participants (13%) were deceased, including six deaths attributed to a meningiom
232 in 89 normal kidney samples from living and deceased kidney donors and normal poles of nephrectomies
233 omes in a prospective cohort study involving deceased kidney donors from five organ procurement organ
239 on with DHA as observed in vivo, resulted in deceased Notch 1/Jagged 1 protein expression however, DH
242 The influence of preference for type of KT (deceased or living donor) and transplant center location
245 idney donation offers superior outcomes over deceased organ donation, but incurs psychosocial and eth
248 ntions on increasing the willingness to be a deceased organ donor (measured as commitment to donate a
253 Our primary outcome measure was potential deceased organ donors (identified by the presence of dia
261 After the 2013 modification, over 20% of all deceased organ donors in the United States were identifi
265 sequencing (RNA-seq) on islets from multiple deceased organ donors, including children, healthy adult
268 om 2009-2012, 96,028 (3.3%) were a "possible deceased-organ donor." The two proposed metrics of OPO p
272 etic, and transcriptional data available for deceased participants of the Religious Orders Study (n =
274 aseline efflux capacity was not different in deceased patients and survivors (P=0.60 or P=0.50 for ca
277 s, globus pallidus, and thalamus of these 23 deceased patients were harvested and analyzed with induc
279 Methods We interviewed 2,307 families of deceased patients with advanced lung or colorectal cance
281 mily overrule of donation of solid organs by deceased patients, and examine arguments both in favor o
282 amilies to receive money for donation from a deceased person, who is at no risk of harm, will make it
285 l origin of 83% of alleles, and genotypes of deceased recent ancestors for whom no genotype informati
286 who give permission for the removal of their deceased relative's organs for transplantation exist in
288 donation themselves, donate the organs of a deceased relative, or support a transition to an "opt-ou
289 ion commitment cards, donate the organs of a deceased relative, support the transition to an "opt-out
290 We used a database comprising 1.4 million deceased soldiers to identify war orphans and collect in
293 and pathological data were derived from 607 deceased subjects (mean age at death, 89 years; 66% wome
295 nd (6) the characteristics of the family and deceased that affect the request for family consent.
297 erall survival benefit was 62% versus 70% in deceased versus living donor transplanted patients.
298 FLD (143 versus 258 U/L, P = 0.004) or those deceased with no CFLD (143 versus 327U/L, P = 0.006).
299 ncluded 4256 patients with ALS (3125 [73.4%] deceased) with genotype data extended to 7174392 variant
300 low-up of 49 months), 71.6% of patients were deceased, with median survival time of 11 months for tho
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。